Boccaccino, Alessandra

Upfront FOLFOXIRI plus Bevacizumab with or without Atezolizumab in the Treatment of Patients with Metastatic Colorectal Cancer (AtezoTRIBE): A Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial

Antoniotti, C., Rossini, D., Pietrantonio, F., Catteau, A., Salvatore, L., Lonardi, S., Boquet, I., Tamberi, S., Marmorino, F., Moretto, R., et al. (2022) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 280

KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population

Schirripa, M., Nappo, F., Cremolini, C., Salvatore, L., Rossini, D., Bensi, M., Businello, G., Pietrantonio, F., Randon, G., Fucà, G., et al. (2020) · Clinical Colorectal Cancer

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 66

Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer

Randon, G., Intini, R., Cremolini, C., Elez, E., Overman, M. J., Lee, J., Manca, P., Bergamo, F., Pagani, F., Antista, M., et al. (2022) · European Journal of Cancer

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 24

Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO

Rossini, D., Boccaccino, A., Sbrana, A., Daniel, F., Borelli, B., Raimondi, A., Santini, D., Conca, V., Tomasello, G., Caponnetto, S., et al. (2021) · ESMO Open

Neutropenia and Cancer InfectionsColorectal Cancer Treatments and Studies

Cited by 7